Navigation Links
Evidence shows that anti-depressants likely do more harm than good, researchers find
Date:4/24/2012

HAMILTON, ON, April 24, 2012 Commonly prescribed anti-depressants appear to be doing patients more harm than good, say researchers who have published a paper examining the impact of the medications on the entire body.

"We need to be much more cautious about the widespread use of these drugs," says Paul Andrews, an evolutionary biologist at McMaster University and lead author of the article, published today in the online journal Frontiers in Psychology.

"It's important because millions of people are prescribed anti-depressants each year, and the conventional wisdom about these drugs is that they're safe and effective."

Andrews and his colleagues examined previous patient studies into the effects of anti-depressants and determined that the benefits of most anti-depressants, even taken at their best, compare poorly to the risks, which include premature death in elderly patients.

Anti-depressants are designed to relieve the symptoms of depression by increasing the levels of serotonin in the brain, where it regulates mood. The vast majority of serotonin that the body produces, though, is used for other purposes, including digestion, forming blood clots at wound sites, reproduction and development.

What the researchers found is that anti-depressants have negative health effects on all processes normally regulated by serotonin.

The findings include these elevated risks:

  • developmental problems in infants
  • problems with sexual stimulation and function and sperm development in adults
  • digestive problems such as diarrhea, constipation, indigestion and bloating
  • abnormal bleeding and stroke in the elderly

The authors reviewed three recent studies showing that elderly anti-depressant users are more likely to die than non-users, even after taking other important variables into account. The higher death rates indicate that the overall effect of these drugs on the body is more harmful than beneficial.

"Serotonin is an ancient chemical. It's intimately regulating many different processes, and when you interfere with these things you can expect, from an evolutionary perspective, that it's going to cause some harm," Andrews says.

Millions of people are prescribed anti-depressants every year, and while the conclusions may seem surprising, Andrews says much of the evidence has long been apparent and available.

"The thing that's been missing in the debates about anti-depressants is an overall assessment of all these negative effects relative to their potential beneficial effects," he says. "Most of this evidence has been out there for years and nobody has been looking at this basic issue."

In previous research, Andrews and his colleagues had questioned the effectiveness of anti-depressants even for their prescribed function, finding that patients were more likely to suffer relapse after going off their medications as their brains worked to re-establish equilibrium.

With even the intended function of anti-depressants in question, Andrews says it is important to look critically at their continuing use.

"It could change the way we think about such major pharmaceutical drugs," he says. "You've got a minimal benefit, a laundry list of negative effects some small, some rare and some not so rare. The issue is: does the list of negative effects outweigh the minimal benefit?"


'/>"/>

Contact: Wade Hemsworth
hemswor@mcmaster.ca
905-525-9140 x27988
McMaster University
Source:Eurekalert

Related biology news :

1. NIST/UMass study finds evidence nanoparticles may increase plant DNA damage
2. UNH research adds to mounting evidence against popular pavement sealcoat
3. Strong scientific evidence that eating berries benefits the brain
4. Research reveals first evidence of hunting by prehistoric Ohioans
5. Society of Interventional Radiology explores IR evidence in patient care
6. Evidence of past Southern hemisphere rainfall cycles related to Antarctic temperatures
7. Archaeologists find new evidence of animals being introduced to prehistoric Caribbean
8. Evidence supports ban on growth promotion use of antibiotics in farming
9. Researcher provides further evidence that slow eating reduces food intake
10. UA scientists find evidence of Roman period megadrought
11. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/7/2016)... San Diego (PRWEB) , ... December 07, 2016 ... ... safety data from its phase I/II dose escalation and expansion clinical trial for ... 2016 in Vienna, Austria. The purpose of the trial was to determine the ...
Breaking Biology Technology: